YOLFTbeta
Braveheart Bio, Inc. Common Stock

Braveheart Bio, Inc. Common Stock

BRVE · NASDAQ · Healthcare / Biotechnology

19.62USD-0.88 (-4.29%)

Price History

Full chart

Market Stats

Previous Close20.50
Open20.41
Day Range19.18 – 20.41
52-Week Range20.53 – 32.00
Volume536.60K
Market Cap2.10B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.74
Dividend Yield0.00%
50-Day Avg26.96
200-Day Avg26.96

About

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Travis Murdoch B.S., M.D., M.Sc.
  • Employees49
  • HeadquartersOne Letterman Drive, San Francisco, CA, United States, 94129, USA
  • Websitehttps://www.braveheart.bio

Leadership

  • Dr. Travis Murdoch B.S., M.D., M.Sc.CEO, President & Director · b. 1985
  • Mr. James Paul Rickey CPAChief Financial Officer · b. 1979
  • Ms. Michele A. AndersonChief Development Officer · b. 1967
  • Mr. Marc Evanchik M.S.Chief Scientific Officer · b. 1973
  • Ms. Natalie Dement J.D.VP & Head of Legal
  • Mr. Timothy Y. ZhouDirector of Corporate Development
  • Ms. Steph PalenciaAssociate Director of Human Resources & Office Manager
  • Ms. Brittany de TempleSenior Vice President of Development Operations
  • Dr. Emil M. deGoma M.D.Chief Medical Officer · b. 1976
  • Mr. Tyler Chavez Ph.D.Chief Business Officer · b. 1989

Financials

Income Statement

Currency: USD2025-12-31
Total Revenue0
Operating Income-4.50M
Net Income-66.05M
R&D1.49M

Balance Sheet

Currency: USD2025-12-31
Total Assets89.35M
Total Liabilities155.22M
Total Equity-65.87M
Cash89.16M

Cash Flow

Currency: USD2025-12-31
Operating Cash Flow-2.01M
Financing Cash Flow124.74M
Capital Expenditure33.57M
Free Cash Flow-35.58M
FCF to OCF1766.78%

Earnings

Report DateSep 8, 2026
EPS Estimate-0.25
EPS Actual-2.51
Surprise-904.00%
TimingAfter-hours

Key Statistics & Ratios

Market Cap2.10B
Enterprise Value1.81B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
EPS-1.74
Book Value-11.48
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding90.04M
Shares Float304.24K
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
19.18%
Insiders
58.16%
Retail / Other
22.66%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    43.04K0.06%
  • Fidelity Disruptive Medicine ETF
    11.80K0.02%
  • Vanguard Russell 2000 ETF
    7.92K0.01%
  • Pacific Select Health Sciences I
    7.30K0.01%
  • T. Rowe Price Health Care ETF
    3.50K0.01%
  • Vanguard Russell 2000 Growth ETF
    7890.00%
  • Vanguard Balanced Index Inv
    7310.00%
  • Private Suite Wellington EqGlbRshGEURAcc
    6660.00%
  • Vanguard MStar Inst Ttl StkMktIdxInstlPl
    6520.00%
  • Vanguard U.S. Eq Idx £ Acc
    5200.00%
  • Interfund Equity Team USA I
    3870.00%
  • Vanguard Russell 2000 Value ETF
    2870.00%
  • Vanguard Russell 3000 ETF
    1150.00%